Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Author:

Kanakry Christopher G.1,Hess Allan D.2,Gocke Christopher D.3,Thoburn Christopher2,Kos Ferdynand2,Meyer Christian2,Briel Janet1,Luznik Leo1,Smith B. Douglas1,Levitsky Hyam1,Karp Judith E.1

Affiliation:

1. Division of Hematologic Malignancies and

2. Division of Immunology, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and

3. Division of Hematopathology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD

Abstract

AbstractFew published studies characterize early lymphocyte recovery after intensive chemotherapy for acute myelogenous leukemia (AML). To test the hypothesis that lymphocyte recovery mirrors ontogeny, we characterized early lymphocyte recovery in 20 consecutive patients undergoing induction timed sequential chemotherapy for newly diagnosed AML. Recovering T lymphocytes were predominantly CD4+ and included a greatly expanded population of CD3+CD4+CD25+Foxp3+ T cells. Recovering CD3+CD4+CD25+Foxp3+ T cells were phenotypically activated regulatory T cells and showed suppressive activity on cytokine production in a mixed lymphocyte reaction. Despite an initial burst of thymopoiesis, most recovering regulatory T cells were peripherally derived. Furthermore, regulatory T cells showed marked oligoclonal skewing, suggesting that their peripheral expansion was antigen-driven. Overall, lymphocyte recovery after chemotherapy differs from ontogeny, specifically identifying a peripherally expanded oligoclonal population of activated regulatory T lymphocytes. These differences suggest a stereotyped immunologic recovery shared by patients with newly diagnosed AML after induction timed sequential chemotherapy. Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference46 articles.

1. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.;Kantarjian;Cancer,2008

2. Immunotherapy for myeloid leukemias: current status and future directions.;el-Shami;Leukemia,2008

3. T-cell phenotypic profile and colony formation during recovery from cytotoxic therapy-induced marrow aplasia.;Ashkenazi;Cancer Res,1985

4. Reduction and repopulation of T-lymphocytes after cytoreductive therapy with or without autologous bone marrow rescue.;Gratama;Exp Hematol,1986

5. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia.;Panoskaltsis;Leukemia,2003

Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3